0.9% saline vs. Plasma-Lyte 148 for Intensive Care Fluid Therapy. (the SPLIT study)
Phase 3
Completed
- Conditions
- Intravenous Fluid Management in Critical IllnessCardiovascular - Other cardiovascular diseasesAnaesthesiology - Other anaesthesiologyInfection - Other infectious diseases
- Registration Number
- ACTRN12613001370796
- Lead Sponsor
- Medical Research Institute of New Zealand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
Patients admitted to the study ICU who require crystalloid fluid therapy
Exclusion Criteria
1. patients currently receiving or expected to require renal replacement therapy within six hours of ICU admission 2. patients who are usually on dialysis for end stage renal failure 3. patients who are admitted to the ICU solely for consideration of organ donation or for palliative care 4. patients previously enrolled in the SPLIT study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients with either acute kidney injury or failure based on on creatinine levels in accordance with RIFLE criteria[Highest value measured during the patient's stay in the Intensive Care Unit (censored at day 90)]
- Secondary Outcome Measures
Name Time Method